ABIVAX Société Anonyme Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

ABIVAX Société Anonyme wird ein jährliches Gewinn- und Umsatzwachstum von 2.4% bzw. 66.1% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich sinken um 4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -236.6% betragen.

Wichtige Informationen

2.4%

Wachstumsrate der Gewinne

-4.0%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	37.0%
Wachstumsrate der Einnahmen	66.1%
Zukünftige Eigenkapitalrendite	-236.6%
Analystenabdeckung	Good
Zuletzt aktualisiert	14 Oct 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

LSE:0RA9 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	7	-216	-201	-201	7
12/31/2025	6	-194	-182	-181	7
12/31/2024	8	-166	-123	-123	7
6/30/2024	9	-177	-155	-155	N/A
3/31/2024	7	-163	-126	-126	N/A
12/31/2023	4	-148	-97	-97	N/A
9/30/2023	4	-120	-77	-77	N/A
6/30/2023	4	-92	-57	-57	N/A
3/31/2023	4	-76	-56	-55	N/A
12/31/2022	4	-61	-54	-54	N/A
9/30/2022	8	-54	N/A	N/A	N/A
6/30/2022	2	-47	-46	-46	N/A
3/31/2022	1	-45	-46	-46	N/A
12/31/2021	4	-42	-45	-45	N/A
9/30/2021	0	-41	N/A	N/A	N/A
6/30/2021	0	-39	-46	-45	N/A
3/31/2021	0	-38	-38	-38	N/A
12/31/2020	0	-38	-31	-30	N/A
9/30/2020	0	-35	N/A	N/A	N/A
6/30/2020	0	-32	-25	-24	N/A
3/31/2020	0	-31	-27	-26	N/A
12/31/2019	0	-31	-28	-27	N/A
9/30/2019	0	-27	-23	-22	N/A
6/30/2019	0	-23	-18	-17	N/A
3/31/2019	1	-19	-17	-16	N/A
12/31/2018	1	-16	-15	-15	N/A
9/30/2018	1	-14	-14	-13	N/A
6/30/2018	1	-13	-12	-11	N/A
3/31/2018	1	-12	N/A	-10	N/A
12/31/2017	0	-11	N/A	-8	N/A
9/30/2017	0	-11	N/A	N/A	N/A
6/30/2017	0	-12	N/A	-11	N/A
3/31/2017	0	-13	N/A	-14	N/A
12/31/2016	0	-14	N/A	-16	N/A
9/30/2016	0	-16	N/A	N/A	N/A
6/30/2016	0	-17	N/A	-24	N/A
3/31/2016	0	-17	N/A	-19	N/A
12/31/2015	0	-16	N/A	-15	N/A
9/30/2015	0	-14	N/A	N/A	N/A
6/30/2015	0	-12	N/A	N/A	N/A
3/31/2015	0	-8	N/A	N/A	N/A
12/31/2014	0	-5	N/A	-3	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 0RA9 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: 0RA9 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: 0RA9 wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: 0RA9Die Einnahmen des Unternehmens (66.1% pro Jahr) werden voraussichtlich schneller wachsen als der Markt UK (3.6% pro Jahr).

Hohe Wachstumseinnahmen: 0RA9Die Einnahmen des Unternehmens (66.1% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 0RA9 wird voraussichtlich in 3 Jahren unrentabel sein.

ABIVAX Société Anonyme Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

No longer forecast to breakeven

Forecast breakeven date moved forward to 2022

Forecast breakeven date moved forward to 2022

Forecast to breakeven in 2024

No longer forecast to breakeven

Recent updates

ABIVAX Société Anonyme has filed a Follow-on Equity Offering in the amount of €150 million.

Abivax SA Announces Board Observer & Advisor Appointments

Abivax SA Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax SA Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25Mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2- Years of Open-Label Maintenance

New minor risk - Share price stability

Abivax SA Provides Updates on Ongoing Clinical Trials

Abivax SA Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Preclinical Colon Cancer Model At Digestive Disease Week 2024

New major risk - Revenue and earnings growth

ABIVAX Société Anonyme Appoints Ana Sharma as Global Head of Quality

Abivax Announces Update to Obefazimod Phase 2B Clinical Development Program in Moderately to Severely Active Crohn’s Disease

Abivax to Host KOL Investor Event to Review Phase 2B Clinical Data and Phase 3 Trial Design for Obefazimod in Patients with Moderately to Severely Active Ulcerative Colitis

New minor risk - Share price stability

New major risk - Revenue and earnings growth

ABIVAX Société Anonyme has filed an IPO in the amount of $100 million.

New major risk - Revenue and earnings growth

Abivax SA Appoints Patrick Malloy as Senior Vice President Investor Relations

ABIVAX Société Anonyme Announces Board Changes

Abivax Appoints Ida Hatoum as Chief People Officer

No longer forecast to breakeven

ABIVAX Société Anonyme, Annual General Meeting, May 05, 2023

No longer forecast to breakeven

Abivax Receives FDA Agreement on Pediatric Development Plan with Obefazimod in IBD

Insufficient new directors

Abivax Sa Announces First Us Patient Enrolled in Global Phase 3 Program with Obefazimod in Ulcerative Colitis

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax SA Announces Phase 2B Study Results of Obefazimod (Abx464) in Ulcerative Colitis Published in the Lancet Gastroenterology & Hepatology

Abivax Phase 3 Program with Obefazimod in Ulcerative Colitis Progresses with US IRB Approval

Forecast breakeven date moved forward to 2022

Insufficient new directors

Abivax Reports One-Year Efficacy and Safety Data of Abx464 Phase 2B Maintenance Trial in Ulcerative Colitis

Forecast breakeven date moved forward to 2022

Abivax SA Announces the Detailed Results of the Dose Escalation Phase of Its Clinical Phase 1/2 Study Conducted with ABX196

Forecast to breakeven in 2024

Abivax SA Receives FDA Feedback with Guidance on Advancing ABX464 into Phase 3 Clinical Testing in Ulcerative Colitis

No longer forecast to breakeven

Forecast to breakeven in 2021

Abivax Reports Excellent Phase 2A Clinical Safety and Efficacy Results with 50Mg ABX464 in Rheumatoid Arthritis

ABIVAX Société Anonyme Reports Excellent Efficacy and Safety of ABX464 in Phase 2B Clinical Trial in Ulcerative Colitis and Plans to Proceed to Phase 3

Abivax Follows DSMB Recommendation to Stop the Phase 2B/3 Mir-Age Covid-19 Clinical Trial Due to Lack of Efficacy

Abivax Publishes Data of ABX464 Induction and Long-Term Maintenance Phase 2A Ulcerative Colitis Study in the Journal "Gastroenterology"

Abivax Appoints Sophie Biguenet as Chief Medical Officer

Abivax Establishes Clinical, Regulatory and Manufacturing Framework for ABX464 Phase 3 Program and Potential Commercialization in 2021

ABIVAX Société Anonyme to Report First Half, 2021 Final Results on Sep 30, 2021

ABIVAX Société Anonyme to Report First Half, 2021 Results on Sep 23, 2021

Abivax Completes Recruitment of Abx464 Phase 2B Induction Study in Ulcerative Colitis

ABIVAX Société Anonyme has completed a Follow-on Equity Offering in the amount of €27.999994 million.

First half earnings released

Abivax Provides an Update on Its Pipeline Progress

ABIVAX SociÃ©tÃ© Anonyme to Report First Half, 2020 Results on Sep 30, 2020

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken